Premium
Stimulation of phosphoinositide hydrolysis by ibotenic acid in cerebellar neurons via two glutamate receptor subtypes
Author(s) -
Raulli Robert,
Wroblewski Jarda T.
Publication year - 1991
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430240408
Subject(s) - ibotenic acid , cnqx , nmda receptor , chemistry , pertussis toxin , metabotropic glutamate receptor 1 , glutamate receptor , biochemistry , metabotropic receptor , receptor , ampa receptor , metabotropic glutamate receptor , biophysics , biology , endocrinology , g protein , central nervous system
In primary cultures of cerebellar granule cells, ibotenate produced a dose‐dependent biphasic stimulation of phosphoinositide (PI) hydrolysis. The high‐affinity component of ibotnate action (EC 50 = 100 nM) was characteristic of the metabolotropic glutamate receptor activation. The action of ibotenate, like that of quisqualate, was inhibited by pretreatment of granule cells with pertussis toxin, confirming the participation of a guanosine triphosphate (GTP)‐binding protein in ibotenate signal transduction. In contrast, the low‐affinity component of ibotenate‐stimulated PI hydrolysis (EC 50 = 100 μM) exhibited the pharmacology of the N ‐methyl‐D‐aspartate (NMDA) receptor. This action was inhibited by NMDA receptor antagonists 3‐(2‐carboxy‐piperazin‐4‐yl)propyl‐1‐phosphonic acid (CPP) and (+)5‐methyl‐10, 11‐dihydro‐5H‐dibenzocyclohepten‐5, 10‐imine maleate (MK‐801) and was potentiated by glycine. Moreover it was inhibited by 6‐cyano‐7‐nitroquinoxaline‐2,3‐dione (CNQX), acting as an antagonist at the positive modulatory site of the NMDA receptor. The low‐affinity component of ibotenate‐induced Pl hydrolysis correlated well with the ability of ibotenate to induced 45 Ca 2+ influx, confirming the action of ibotenate at the ionotropic NMDA receptor. Thus, in cerebellar granule cells, ibotenate appears to stimulate Pl hydrolysis by acting at two distinct glutamate receptor subtypes.